Trial intelligence / Profile preview

Vildagliptin vs Metformin in Elderly Drug Naive T2DM Patients

NCT00383578Phase 3Completed

Sponsor
Novartis
Start
Sep 2006
Primary completion
May 2008
Modality
Small Molecules
Countries
2
01

Overview

Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Sep 2006; status: completed.

02

Drugs

vildagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT00383578.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00383578.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call